OncoMatch/Clinical Trials/NCT06290505
A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study
Is NCT06290505 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Durvalumab for esophageal cancer.
Treatment: Durvalumab — The purpose of this study is to investigate the effects of the addition of the stereotactic body radiotherapy and durvalumab to a well tolerated 2 week chemotherapy and radiation treatment regimen in people with esophageal cancer that is locally advanced or has spread to another area of the body (metastasized).
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Biomarker criteria
Excluded: HER2 (ERBB2) positivity (IHC 2+ or more and HER2 gene amplification on in situ hybridisation)
Known tumour HER2 positivity (IHC 2+ or more and HER2 gene amplification on in situ hybridisation) if oligometastatic disease
Allowed: PD-L1 (CD274) expression
Tumour tissue ... should be available for PD-L1 and mismatch repair (MMR) protein expression ... Patients will not be selected by PD-L1 or MMR status.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Previous systemic therapy for oesophageal or GOJ carcinoma
Cannot have received: thoracic radiotherapy
Exception: Prior palliative radiotherapy to bony metastases is permitted
Previous thoracic radiotherapy. Prior palliative radiotherapy to bony metastases is permitted.
Cannot have received: anti-PD-1 therapy
Prior therapy with an anti-PD1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways
Lab requirements
Blood counts
WBC ≥ 2 x 10^9/L; ANC ≥ 1.5 x 10^9/L; Platelets ≥ 100 x 10^9/L; Haemoglobin ≥ 90g/L
Kidney function
Serum creatinine ≤ 1.5 x ULN; Creatinine clearance (CrCl) ≥ 40 mL/min using Cockroft-Gault formula
Liver function
Alanine transferase ≤ 2.5 x ULN; Aspartate transferase ≤ 2.5 x ULN; Total bilirubin ≤ 1.5 x ULN (≤ 5 x ULN if Gilbert's Syndrome)
Adequate bone marrow function ... Adequate liver function ... Adequate renal function ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify